Core Viewpoint - The article highlights a significant surge in the biopharmaceutical and innovative drug sectors, driven by a major deal between 3SBio and Pfizer, marking a new wave of opportunities for Chinese innovative drug companies [1][4][10]. Group 1: Market Performance - A-shares saw strong performances with 3SBio hitting a 20% limit-up, while other companies like Rongchang Bio and Kexing Pharmaceutical rose over 10% [2]. - In the Hong Kong market, 3SBio's stock surged over 40% during the day, closing up 32.28%, significantly outperforming the broader market [2]. - The Hang Seng Medical Index ETF (159557) rose by 3.94%, indicating strong investor interest in the healthcare sector [2]. Group 2: Major Transactions - 3SBio and its subsidiaries entered a $6 billion deal with Pfizer for the global development and commercialization of a dual-target antibody, setting a record for upfront payments in recent years for Chinese innovative drugs [4][5]. - This transaction is seen as a catalyst for a broader revaluation of the entire industry [6]. Group 3: Industry Trends - The article notes a significant increase in License-out transactions by Chinese pharmaceutical companies, with 94 deals totaling $51.9 billion in 2024, a 26% year-on-year increase [8]. - In Q1 2025 alone, there were 41 License-out transactions amounting to $36.93 billion, nearing the total for all of 2023 [8]. - Major companies like Hengrui Medicine and Innovent Biologics have also secured substantial deals, reflecting a trend of increasing international collaboration [8]. Group 4: Innovation and Development - As of December 31, 2024, Chinese companies have developed 3,575 active innovative drugs, surpassing the U.S. and leading globally [17]. - The number of first-in-class (FIC) drugs developed by Chinese firms has increased from 9 in 2015 to 120 in 2024, indicating a growing capability in drug innovation [18]. - The approval rate for domestic drugs has also improved, with 39 drugs approved in 2024, up from less than 10% in 2015 to 42% [19]. Group 5: Investment Opportunities - The article suggests that the current low valuation of the biopharmaceutical sector presents significant investment opportunities, especially as the industry shows signs of recovery [24][37]. - Fund allocations to the innovative drug sector have increased, with a notable rise in heavy positions in Q1 2025 [30]. - ETFs tracking the healthcare sector, such as the Hang Seng Medical Index ETF and the Sci-Tech Innovation Pharmaceutical Index ETF, have seen substantial inflows, indicating strong investor interest [36].

Group 1: Company Overview - Contemporary Amperex Technology Co., Limited (CATL) has successfully listed in Hong Kong, raising HKD 35.657 billion, making it the largest IPO in the Hong Kong market since Kuaishou [1] - CATL's IPO could potentially become the largest globally by 2025 if the over-allotment option is exercised, raising the total to HKD 41 billion [1] Group 2: Market Dynamics - The innovative drug sector is currently experiencing significant growth, with companies like 3SBio seeing stock price increases of over 60% in recent trading days, driven by positive market sentiment [1] - The global market for Type 2 diabetes (T2DM) and obesity treatments is projected to grow significantly, with T2DM expected to reach USD 106.2 billion and obesity USD 58.5 billion by 2032, reflecting compound annual growth rates of 4.9% and 22.9% respectively [9] Group 3: Company Specifics - Paig Biological - Paig Biological, a biotechnology company focused on chronic disease therapies, is currently in the process of an IPO in Hong Kong, with a subscription period from May 19 to May 22, 2025 [2][5] - The company has undergone multiple rounds of financing, with a post-money valuation of approximately CNY 4 billion as of June 2023 [4] Group 4: Product Pipeline and Competition - Paig Biological's core product, PB-119, is a GLP-1 receptor agonist aimed at treating T2DM and obesity, with its NDA for T2DM accepted by the National Medical Products Administration in September 2023 [9][10] - The competitive landscape for PB-119 is challenging, with 13 competitors in the T2DM space and over 15 in the obesity treatment sector, including established players like Novo Nordisk and Eli Lilly [10] Group 5: Financial Performance - Paig Biological has reported net losses of CNY 306 million, CNY 279 million, and CNY 283 million for the years 2022, 2023, and 2024 respectively, alongside significant R&D expenditures [11]

01 5月19日，据彭博报道，在美日财长本周谈判前夕，对冲基金和长期投资者正重新建立押注日元升值的头寸，创下五年高位，而且期权市场也显示出投资 者对日元升值的预期。 2. 国有六大行今日集体下调存款利率 一年期定期存款利率均下调15个基点 中行、农行、工行、建行、邮储银行、交行今日均宣布下调了存款利率，降幅均保持一致。 3. 5年期以上LPR下降10个基点 100万元房贷30年减少2万元 最新一期贷款市场报价利率（LPR）今日出炉，五年期LPR下调至3.5%，此前为3.6%。如以商贷额度100万元、贷款30年、等额本息还款方式计算，此次 LPR下降10个基点，月供将减少56元，30年月供累积减少2万元。 基金经理最新动态 1. 万亿公募高管变更，徐勇卸任 5月19日晚间，招商基金发布高级管理人员变更公告显示，公司总经理徐勇因个人原因离任，由招银理财总裁钟文岳接任。 02 今日基金新闻速览 1. 日元多头又回来了，华尔街重新押注日元升值 ETF方面，港股创新药板块全天强势，景顺长城基金港股创新药50ETF、广发基金港股创新药ETF、港股通创新药ETF工银、万家基金港股通创新药ETF 基金均涨超5%，易方达基金恒 ...

Core Viewpoint - The collaboration between 3SBio and Pfizer for the dual antibody PD-1/VEGF product SSGJ-707 marks a significant milestone in the biopharmaceutical industry, with a record-breaking upfront payment of $1.25 billion and potential total payments exceeding $6 billion, highlighting the growing interest and investment in innovative cancer therapies [1][3][4]. Group 1: Financial Aspects - The deal includes an upfront payment of $1.25 billion, making it the highest upfront payment for a domestic transaction in China to date [1]. - The total potential payments could reach $4.8 billion in milestone payments, bringing the total deal value to over $6 billion [1]. - 3SBio's stock price has surged over 200% since February, with a market capitalization increase of approximately HKD 30 billion [3]. Group 2: Product Development and Market Potential - SSGJ-707 has shown significant anti-tumor activity and safety in early clinical trials, positioning it as a potential best-in-class therapy [3][6]. - The product is currently undergoing four Phase II clinical studies targeting various cancers, with projected peak sales of approximately RMB 4 billion domestically and $4.5 billion in overseas markets [3][4]. - The product has received breakthrough therapy designation for treating PD-L1 positive non-small cell lung cancer (NSCLC) [4]. Group 3: Strategic Implications for Pfizer - Pfizer is actively seeking new products to bolster its portfolio, especially after a significant revenue drop in 2023 [5]. - The collaboration with 3SBio allows Pfizer to enhance its offerings in the PD-1/VEGF space, where it has previously engaged in clinical collaborations [6]. - The urgency for Pfizer to acquire new blockbuster products is underscored by its recent challenges in the GLP-1 drug development space [5].

三连跌后，港股终于迎来反弹。 周二，港股三大指数高开高走，市场热点轮动加速，生物医药、创新药等板块发起强势猛攻。 | ● 热力图 ○ 列表 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | Wind香港概念板块指数 | | | Wind香港二级行业指数 | | | | | | 影视传媒 | 抗肿瘤 | 创新药 | 本地券商 | 黄金珠宝 | Wind香港电气设 Wind香港医药生 Wind香港家庭用 Wind香港硬件设 Wind香港传 | | | | | | 5.73% | 4.96% | 4.82% | 4.69% | 4.40% | 13.40% | 4.05% | 3.84% | 2.48% | 1.59% | | 智能家居 | 武汉本地 | 生物医疗 | CRO | 智能终端 | Wind香港汽车与 Wind香港电信服 Wind香港环保II Wind香港有色金 Wind香港家中 | | | | | | 3.82% | 3.80% | 3.75% | 3.43% | 3.38% ...

Group 1: Market Performance - Hong Kong pharmaceutical stocks experienced a strong rally, with Sihuan Pharmaceutical rising over 35%, Zhaoke Ophthalmology-B increasing over 13%, and CSPC Pharmaceutical gaining 7% [1] - Various Hong Kong-listed innovative drug ETFs saw significant gains, with the ICBC Hong Kong Innovative Drug ETF up over 5% and several others rising over 4% [1] Group 2: Positive Industry News - Sihuan Pharmaceutical entered a licensing agreement with Pfizer, receiving an upfront payment of $1.25 billion and potential total payments of up to $4.8 billion, along with a double-digit royalty on sales [2] - Zhaoke Ophthalmology announced that the National Medical Products Administration of China accepted its new drug application for cyclosporine eye gel, which has shown good efficacy and safety in clinical trials [2] - CSPC Pharmaceutical's CPO301 received its third Fast Track designation from the FDA for treating advanced non-small cell lung cancer, indicating strong regulatory support for its innovative therapies [3] Group 3: Fund Holdings and Market Sentiment - Public fund holdings in the pharmaceutical sector showed an increase, with A+H shares accounting for 9.05% and A-shares for 9.23%, reflecting a positive sentiment towards the industry [4] - The top five public funds by holdings included companies like Heng Rui Medicine and WuXi AppTec, indicating strong institutional interest in these firms [4] - Long-term outlook for the pharmaceutical sector remains optimistic due to favorable policies and the increasing demand for innovative therapies, with recommendations to focus on high-efficiency management and quality product pipelines [5]

Group 1 - The Hang Seng Index rose by 1.29%, gaining 301 points to close at 23,634 points, while the Hang Seng Technology Index increased by 1.32% and the Hang Seng Biotechnology Index surged by 4.26% [1] - Ningde Times (03750) saw a significant increase of over 16% on its first day of trading on the Hong Kong Stock Exchange [1] - 3SBio (01530) experienced a dramatic rise of 35%, nearing its historical high, following an authorization agreement with Pfizer for a PD-1/VEGF dual antibody, with Pfizer making an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] Group 2 - Yiming Anke-B (01541) rose over 10% after receiving a $5 million payment from Axion Bio, indicating a promising outlook in the self-immune field for IMM0306 [2] - Basilea Pharmaceuticals-B (02616) increased by over 18% after presenting five new research results at the 2025 AACR conference [2] - Rongchang Bio (09995) rose over 14% due to the addition of new indications for Vidi Xi monoclonal antibody, with Q1 performance slightly exceeding expectations [2] Group 3 - Xiaomi Group-W (01810) increased by nearly 4% ahead of the release of multiple new products, with its self-developed SoC "Xuanjie" expected to launch soon [5] - Alibaba Pictures (01060) surged over 17%, reporting an adjusted EBITDA profit of 809 million yuan for the year, a 61% year-on-year increase [6] - Alibaba Health (00241) fell over 4% post-earnings despite a more than 62% year-on-year increase in net profit, as it did not declare a final dividend [6]

Core Viewpoint - The collaboration between 3SBio and Pfizer marks a significant advancement in the licensing of domestic bispecific antibodies, reflecting the growing confidence in the clinical value of SSGJ-707 and the potential for accelerated global commercialization [1][11]. Group 1: Licensing Agreement Details - 3SBio and its affiliates granted Pfizer exclusive rights to develop, manufacture, and commercialize the PD-1/VEGF bispecific antibody SSGJ-707 globally, excluding mainland China [1]. - Pfizer will pay a non-refundable upfront fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion, plus a tiered percentage of sales based on the product's revenue in the licensed regions [1][2]. - The agreement includes a multi-layered cooperation model, allowing 3SBio to retain commercialization rights in mainland China while granting Pfizer rights in other regions [2]. Group 2: Market Context and Implications - The upfront payment of $1.25 billion represents 21% of the total potential deal value, significantly higher than the industry average of 10%-15%, indicating Pfizer's confidence in SSGJ-707's clinical prospects [2]. - The collaboration is seen as a strategic move for Pfizer to enter the PD-1/VEGF market, which is expected to grow rapidly, especially as it competes with established players like Merck and Bristol-Myers Squibb [2][11]. - The bispecific antibody market has seen a surge in interest, with the transaction value for domestic bispecific antibodies rising from $1.5 million in 2019 to $707.4 million in 2022, and projected to reach $1.571 billion by 2024 [6][10]. Group 3: Clinical Development and Future Prospects - SSGJ-707 has shown promising results in clinical trials for non-small cell lung cancer (NSCLC), achieving high objective response rates and disease control rates, positioning it as a best-in-class candidate [5]. - The drug has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China and is currently in various stages of clinical trials in both China and the U.S. [5][11]. - The increasing focus on bispecific antibodies is expected to drive significant growth in the market, with projections indicating a compound annual growth rate (CAGR) exceeding 35% over the next three years [11].

中国基金报记者卢鸰 中国创新药出海又有大消息。 5月20日早间，三生制药（01530.HK）发布公告称，公司及附属子公司沈阳三生、三生国健与辉瑞签署 协议，将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF双特异性抗体SSGJ-707在全球（不包括中 国内地）的开发、生产、商业化权利。公司及沈阳三生将保留SSGJ-707在中国内地的开发、生产、商 业化权利，并基于届时商定的财务条款，授予辉瑞对SSGJ-707在中国内地开展商业化的选择权。 根据协议，三生制药将获得12.5亿美元不可退还且不可抵扣的首付款，以及最高可达48亿美元的开发、 监管批准和销售里程碑付款。公司还将根据授权地区的产品销售额收取两位数百分比的梯度销售分成。 此外，辉瑞将于协议生效日认购三生制药价值1亿美元的普通股股份。 国盛证券医药研究团队认为，此次三生制药与辉瑞的合作，其首付款、里程碑等均超预期；中国的第二 波创新药浪潮已经到来，这是中国创新药出海"从0到1"的浪潮。 SSGJ-707是三生制药基于CLF2专利平台开发的靶向PD-1/VEGF双特异性抗体，可同时抑制PD-1和 VEGF双靶点，具有同类最优（best-in-class） ...

Group 1 - The Hong Kong pharmaceutical sector is experiencing a strong upward trend, with the China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 2.76% as of May 20, 2025 [1] - Notable individual stock performances include a 6.73% increase in CSPC Pharmaceutical Group and a 6.67% rise in Innovent Biologics [1] - The Hong Kong Medical ETF has seen a cumulative increase of 3.51% over the past week, reflecting positive market sentiment [1] Group 2 - Three-Sixty Biopharma's stock surged over 30% after announcing an exclusive global licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody SSGJ-707, with an upfront payment of $1.25 billion and potential milestone payments up to $4.8 billion [1] - The licensing agreement includes a double-digit percentage royalty on net sales in licensed regions, and Pfizer may also subscribe to $100 million in new shares of Three-Sixty Biopharma [1] - Analysts expect a shift in market focus from earnings to fundamental changes in the industry and companies starting in May, with a continued positive outlook on innovative drugs and companies expanding into emerging markets [2] Group 3 - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index consists of 50 highly liquid and large-cap healthcare companies, with the top ten stocks accounting for 60.54% of the index [2]